Ctrl/Cmd K

Loading stock analysis…

Explore

Stocks
Screener
IPOs
News

Tools

Backtest
Portfolio
Wealth
ITR

Learn

Guides
Methodology

Company

About
Contact
Disclosures
Privacy
Terms

© 2026 Anvest. All rights reserved.

Designed & Engineered in India·harsh@anvest.in

Disclaimer: Anvest provides financial analytics, screening simulations, and planning tools for informational and educational purposes only. Anvest is not a SEBI-registered investment advisor or broker. Nothing herein constitutes investment advice or an offer to buy/sell securities. Full details on methodology and limitations are documented under Disclosures and Terms.

Stocks›Healthcare

Concord Biotech Limited

CONCORDBIO · NSE · Healthcare · As of 30 Oct 2026Delayed / Sandbox EOD Data

₹1,245.60

+₹15.00 (+1.22%)(1D)

₹987.0052 Week Range₹1,615.00

Chart Score AI Profile Fundamentals Technicals Financials Shareholding Peers Filings

Anvest Score

50/100

Valuation

0/100

Quality

62/100

Growth

40/100

Health

100/100

Momentum

57/100

Valuation
0
Quality
62
Growth
40
Health
100
Momentum
57

Loading company profile…

Loading fundamentals…

Loading technical indicators…

Loading financial statement…

Loading shareholding…

Loading peer comparison…

Loading filings…

More Page Context

Research at a glance

Concord Biotech Limited with delayed price, financials, ownership context, and peer links.

Latest price

₹1,245.6

Market cap

₹13,031 Cr

P/E ratio

46.63

P/B ratio

6.46

Dividend yield

Not available

ROE

Not available

RSI 14

39.67

1Y return

Not available

Concord Biotech Limited FAQs

3 topics

ExpandCollapse

Related paths

Peer links appear when comparable names are available.

Open screener Curated screens Backtest ideas

What does the Concord Biotech Limited (CONCORDBIO) stock page cover?

Concord Biotech Limited on Anvest includes delayed price context, valuation ratios, a one-year price range, and section-level research data when available.

What are the current headline metrics for CONCORDBIO?

Concord Biotech Limited is currently shown with a delayed price near ₹1,245.6, P/E 46.63.

Does the CONCORDBIO page provide investment advice?

No. The CONCORDBIO page is built for research, comparison, and planning. It does not publish buy, sell, or hold recommendations.

Keep exploring

Related insights

ONESOURCE

Onesource Specialty Pharma Limited · Healthcare

BLUEJET

Blue Jet Healthcare Limited · Healthcare

SUPRIYA

Supriya Lifescience Limited · Healthcare

How to Analyze NSE/BSE Concall Transcripts & Management Guidance Using AI

Learn how specialized financial AI analyzes Indian company concalls, extracts capex and margin guidance, and tracks executive promises on Anvest.

AI Company ProfileSign in to generate AI briefing

AI Snapshot

Concord Biotech Limited is an Indian biotechnology company specializing in the development and manufacturing of fermentation-based Active Pharmaceutical Ingredients (APIs) and finished formulations. It holds a strong global market position in niche therapeutic areas like immunosuppressants, oncology, and anti-infectives, exporting to over 70 countries.

BiotechnologyFounded:1984CEO/MD:Tarun Satishbhai VaidyaHQ:Ahmedabad, Gujarat, India

Business profile as of 2026-08-25

Revenue growth: -12.1%FY26 growth
EPS growth: -30.2%FY26 growth
CFO / PAT: 1.02×FY26

What Looks Strong

Cash FlowOperating cash flow was 1.02× total net profit in FY26.

What to Watch

RevenueRevenue declined about 12% in FY26 (consolidated: ₹1,200 cr → ₹1,055 cr). Watch whether the next results confirm a trend or a one-off.
EarningsNet profit fell about 30% in FY26 (consolidated: ₹372 cr → ₹261 cr). Watch margins and one-off items in the next filing.
MarginsOperating margin compressed from ~37.7% to ~27.8% in FY26 (consolidated). Watch input costs and pricing in the next two results.

Reports a single operating segment in its results filings.
They serve pharmaceutical companies worldwide, leveraging their expertise in complex fermentation processes for high-value therapeutic products.
Concord Biotech's business activities are primarily focused on the manufacturing of pharmaceuticals.

FY26 (consolidated): revenue ₹1,055 cr, down 12% from ₹1,200 cr in FY25; net profit ₹261 cr, down 30% from ₹372 cr in FY25.
FY26 (consolidated): operating cash flow ₹267 cr (1.0× net profit); debt/equity 0.00×.
Latest quarter to Sep 2026 (consolidated): revenue ₹309 cr (up 25% year on year); net profit ₹69.6 cr.

The company's financial statements have obtained a 'Reasonable Assurance II' type of assurance